Advanced Antibody Engineering


Monoclonal antibodies (mAbs) have had a huge impact on both diagnostics and treatment of diseases. However, it is still a challenge to design, evaluate and compare the right functions, as well as to optimize them for optimal specificity, affinity, avidity, stability, solubility, expressability, effector-functions, valency, payload(s), etc. Let acib do it for you!


acib key researchers Prof. Florian Rüker and Dr. Gordana Wozniak-Knopp are world-renowned experts on antibody engineering. They have e.g. founded the company F-star Therapeutics (currently 100+ million dollar company NASDAQ-listed company), published the book ‘Introduction to Antibody Engineering’ (ISBN 978-3-030-54629-8), headed the Austrian CD-lab for Innovative Immunotherapeutics, as well as a plenitude of industrial projects and teaching students in Antibody Engineering at the University of Natural Resources and Life Sciences, Vienna (BOKU).


The ‘Modular Antibody Technology’ developed by Prof. Rüker and Dr. Wozniak-Knopp allows the use of Fcabs i.e. Fc fragments able to bind antigens through engineered loops in their CH3 domain, thus creating bi-specific antibodies (binding with their modified Fc-terminus, as well as with their Fab-fragments). They can also modify the CH3-region to form heterodimeric antibodies and mastered fusion of antibody fragments for the generation of IgG-like multi-valent multi-paratopic antibodies to elicit T-lymphocyte-mediated killing more efficiently. They have also developed a method for simplified directional coupling of toxin warheads to antibodies without impairment of reactivity with target cells or negative impact on their biophysical properties. The expertise and methods that acib can offer include phage and yeast display, molecular simulation and modelling, supported by excellent available infrastructure for generation of wet-lab results.


Under protection of a CDA/NDA we provide you with professional strategies for engineering your antibody of choice. Any IP developed in such a project would fully belong to the investor/industrial partner.


Prof. Dr. Florian Rüker, Dr. Gordana Wozniak-Knopp

Available for:

Investments, Joint Research Projects, Contract Research

Development status:

Technology Readiness Level 2-5 (Technology validated in lab)


Will be generated for you as our industrial partner / investor


Antibody Engineering, Rational Design, Directed Evolution, Heterodimeric Antibodies, Bi-Specific Antibodies, Multivalent Antibodies, Humanized Antibodies, Modular Antibody Engineering, Antibody-Drug Conjugates (ADCs), Prolonged Half-Life, Increased affinity

Dr. Martin U. Trinker
Director Business Development & Fundraising
Krenngasse 37
8010 Graz
+43 316 873 9316